CriticalClass Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)×HIV protease inhibitor / pharmacokinetic booster
Updated · Methodology
Mechanism
Ritonavir strongly inhibits the liver enzyme CYP3A, so drugs cleared mainly by CYP3A build up in the blood when taken with it. Their effects and adverse reactions become stronger and last longer (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA). The liver clears quinidine mainly through CYP3A4, and quinidine levels rise, for example, with ketoconazole, probably through competition for this pathway (quinidine label, US Food and Drug Administration, FDA). Quinidine prolongs the corrected QT interval, and the risk of torsade de pointes is higher with high quinidine blood levels, slow heart rate and low potassium, magnesium or calcium (quinidine FDA label). With ritonavir, the risk of arrhythmias and other serious quinidine adverse reactions therefore rises (ritonavir SmPC, EMA). In the other direction, quinidine inhibits CYP2D6, a minor clearance pathway of ritonavir. The quinidine label advises caution with drugs metabolised by CYP2D6 (quinidine FDA label; ritonavir SmPC, EMA).
Symptoms
Prolongation of the corrected QT interval itself causes no symptoms and shows only on the electrocardiogram (ECG). Ventricular arrhythmias cause palpitations, dizziness and fainting. Life-threatening torsade de pointes, frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation have been reported with quinidine (quinidine label, US Food and Drug Administration, FDA). Besides arrhythmias, too much quinidine causes low blood pressure, vomiting, diarrhoea, tinnitus, high-frequency hearing loss, vertigo, blurred and double vision, sensitivity to light, headache, confusion and delirium (quinidine FDA label). Rare second- and third-degree atrioventricular block has been reported with ritonavir in patients with heart disease, conduction abnormalities or other drugs that prolong the PR interval (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA).
Management
The combination is contraindicated. Quinidine is on the ritonavir contraindication list with no dose condition. The contraindication therefore covers both treatment of human immunodeficiency virus (HIV) infection and low-dose ritonavir used to boost another protease inhibitor (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA, and ritonavir label, US Food and Drug Administration, FDA). Quinidine is also contraindicated with the 5-day course of nirmatrelvir plus ritonavir 100 mg every 12 hours (Paxlovid SmPC, EMA). When ritonavir boosts another protease inhibitor, also check the contraindications in that drug's prescribing information (ritonavir SmPC, EMA, and FDA label). Review the full medicine list before starting ritonavir and before adding any new drug for a patient who already takes ritonavir (ritonavir FDA label). The corrected QT interval on the electrocardiogram (ECG) predicts quinidine-induced ventricular arrhythmias better than the quinidine blood level (quinidine FDA label). If the two drugs have been taken together anyway and haemodynamically unstable polymorphic ventricular tachycardia, including torsade de pointes, develops, stop quinidine and perform immediate cardioversion or overdrive pacing (quinidine FDA label). Look for and correct low potassium, magnesium and calcium (quinidine FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Norvir (ritonavir) prescribing information (2026)– AbbVie. NORVIR (ritonavir) tablets, oral solution, oral powder. Prescribing information, DailyMed setid 2849298e-de6e-47bb-8194-56e075b33fc3, sections 4 and 7.2
- AEMPS: Ficha técnica: Ritonavir (nº registro 81039), sección 4.3 (2025)– AEMPS, CIMA, nº registro 81039, revisión 04/2025, sección 4.3
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Nirmatrelvir/ritonavir (EU/1/22/1625), sección 4.3 (2026)– EMA, Paxlovid, ficha técnica en CIMA (nº registro 1221625001), consultada 03.10.2026, secciones 4.3 y 4.5
- FDA: Quinidine Sulfate Tablets USP (quinidine sulfate) prescribing information (2023)– FDA, DailyMed setid b0d6341b-d880-4f0b-8844-bc788c03004a (Epic Pharma), revisión 11/2023, secciones Clinical Pharmacology, Warnings, Precautions (Drug Interactions) y Overdosage